EDMONTON, AB – Aurora Cannabis Inc., a leading global medical cannabis company, completed a multi-year investment of $3 million in improvements to its manufacturing facility in Pemberton, British Columbia. The upgrades are a combination of Aurora’s proprietary high-performing genetics and state-of-the-art engineering design which have resulted in optimal cultivation conditions and expanded output. The site has been renamed to Aurora Alpine – a testament to the site reaching its highest potential and to reflect the facility overlooking Mount Currie in the Pemberton Valley.
“Over the last three years, the investments we’ve made into this facility have resulted in doubling the yield and potency, reaching a record 33.7%,” says Alex Miller, Executive Vice President of Operations and Supply Chain at Aurora. “The name Aurora Alpine reflects our commitment to achieving the highest degree of excellence at a site that’s driven by industry leading genetic technology, and backed by a world-class team that make it all possible.”
The former Whistler Medical Marijuana Company site was licensed in 2019 and was built on a legacy of producing award-winning cannabis. The GACP certified facility enables Aurora to expand its global reach by exporting premium medical cannabis produced from the Aurora Alpine site internationally.
About Aurora Cannabis Inc.
Aurora serves both the medical and consumer markets across Canada, Europe, Australia, and New Zealand. The Company’s adult-use brand portfolio includes Drift, San Rafael ’71, Daily Special, Tasty’s, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., a leading supplier of propagated agricultural plants.
